Follow-up CT findings of tamoxifen-induced non-alcoholic steatohepatitis (NASH) of breast cancer patients treated with bezafibrate

  • Authors:
    • Yasuhiro Ogawa
    • Yoriko Murata
    • Toshiji Saibara
    • Akihito Nishioka
    • Shinji Kariya
    • Shoji Yoshida
  • View Affiliations

  • Published online on: September 1, 2003     https://doi.org/10.3892/or.10.5.1473
  • Pages: 1473-1478
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

One-third of the breast cancer patients who underwent tamoxifen intake showed less than 0.9 of their liver/spleen CT (computed tomography) ratio on their annual CT study, and were diagnosed as having fatty liver (hepatic steatosis). Among them, patients who showed a lower liver/spleen CT ratio of less than 0.5 were recommended to undergo needle biopsy of the liver in order to obtain histopathological confirmation of non-alcoholic steatohepatitis (NASH), with 15 patients undergoing needle biopsy of the liver. As a result, 14 out of the 15 patients were diagnosed as having NASH, and these patients were additionally administered bezafibrate in order to prevent possible progressive changes of NASH into liver cirrhosis. In this study, we show the changes of follow-up CT findings of 6 patients with histopathologically-proven NASH who continued to undergo bezafibrate intake after the diagnosis of NASH. Two patients showed almost complete improvement as indicated by the liver/spleen CT ratio several months after completion of a tamoxifen intake of 5 years, and another 3 showed partial improvement on their liver/spleen CT ratio by bezafibrate intake in spite of continuing tamoxifen intake. Another patient with diabetes mellitus (type II) showed a continually decreasing liver/spleen CT ratio during adjuvant tamoxifen in spite of bezafibrate intake. Therefore, we concluded that the progression of NASH could be prevented by bezafibrate without any interruption of adjuvant tamoxifen treatment. For patients with diabetes mellitus, critical follow-up using CT study and laboratory tests is considered essential.

Related Articles

Journal Cover

September-October 2003
Volume 10 Issue 5

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Ogawa Y, Murata Y, Saibara T, Nishioka A, Kariya S and Yoshida S: Follow-up CT findings of tamoxifen-induced non-alcoholic steatohepatitis (NASH) of breast cancer patients treated with bezafibrate. Oncol Rep 10: 1473-1478, 2003
APA
Ogawa, Y., Murata, Y., Saibara, T., Nishioka, A., Kariya, S., & Yoshida, S. (2003). Follow-up CT findings of tamoxifen-induced non-alcoholic steatohepatitis (NASH) of breast cancer patients treated with bezafibrate. Oncology Reports, 10, 1473-1478. https://doi.org/10.3892/or.10.5.1473
MLA
Ogawa, Y., Murata, Y., Saibara, T., Nishioka, A., Kariya, S., Yoshida, S."Follow-up CT findings of tamoxifen-induced non-alcoholic steatohepatitis (NASH) of breast cancer patients treated with bezafibrate". Oncology Reports 10.5 (2003): 1473-1478.
Chicago
Ogawa, Y., Murata, Y., Saibara, T., Nishioka, A., Kariya, S., Yoshida, S."Follow-up CT findings of tamoxifen-induced non-alcoholic steatohepatitis (NASH) of breast cancer patients treated with bezafibrate". Oncology Reports 10, no. 5 (2003): 1473-1478. https://doi.org/10.3892/or.10.5.1473